Identification of peptides for immunotherapy of cancer. It is still worth the effort

Critical Reviews in Immunology

Volumn 18, Issue 1-2, 1997, Pages 7-27

  Velders, Markwin P ^a   Nieland, John D ^a   Rudolf, Michael P ^a   Loviscek, Kathleen ^a   Weijzen, Sanne ^a   De Visser, Karin E ^a   Fatima Macedo, M ^a   Carbone, Michele ^a   Kast, W Martin ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; BETA CATENIN; CANCER VACCINE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOPHENOL MONOOXYGENASE; PROTEIN P53; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; PEPTIDE;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; PRIORITY JOURNAL; PROTEIN DETERMINATION; T LYMPHOCYTE ACTIVATION; ANIMAL; ARTICLE; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PEPTIDES;

EID: 0030721436     PISSN: 10408401     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (162)

1. Townsend, A. R., Bastin, J., Gould, K., and Brownlee, G. G., Cytotoxic T lymphocytes recognize influenza haemagglutinin that lacks a signal sequence, Nature, 324, 575-577, 1986.
2. Buus, S., Seite, A., Colon, S. M., Miles, C., and Grey, H. M., The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides, Science, 235, 1353-1358, 1987.
3. Rotzschke, O., Falk, K., Deres K., Schild, H., Norda, M., Metzger, J., Jung, G., and Rammensee, H. G., Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells see comments, Nature, 348, 252-254, 1990.
4. Schumacher, T. N., De Bruijn, M. L., Vernie, L. N., Kast, W. M., Melief, C. J. M., Neefjes, J. J., and Ploegh, H. L., Peptide selection by MHC class I molecules, Nature, 350, 703-706, 1991.
5. Neefjes, J. J., and Momburg, F., Cell biology of antigen presentation, Curr. Opin. Immunol., 5, 27-34, 1993.
6. Zinkernagel, R. M. and Doherty, P. C., Restriction of in vitro T-cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system, Nature, 248, 701-702, 1974.
7. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C., Structure of the human class I histocompatibility antigen, HLA-A2, Nature, 329, 506-512, 1987.
8. Bjorkman, P. J., Saper, M. A., Samraoui, B., Bennett, W. S., Strominger, J. L., and Wiley, D. C., The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigens, Nature, 329, 512-518, 1987.
9. Neefjes, J. J. and Ploegh, H. L., Allele-and locus-specific differences in cell surface expression and the association of HLA class I heavy chain with beta 2-microglobulin: differential effects of inhibition of glycosylation on class I subunit association, Eur. J. Immunol., 18, 801-810, 1988.
10. Goldberg, A. L. and Rock, K. L., Proteolysis, proteasomes and antigen presentation, Nature, 357, 375-379, 1992.
11. Goldberg, A. L., Gaczynska, M., Grant, E., Michalek, M., and Rock, K. L., Functions of the proteasome in antigen presentation, Cold Spring Harbor Symposia on Quantitative Biology, 60, 479-490, 1995.
12. Eggers, M., Boes-Fabian, B., Ruppert, T., Kloetzel, P. M., and Koszinowski, U. H., The cleavage preference of the proteasome governs the yield of antigenic peptides, J. Exp. Med., 182, 1865-1870, 1995.
13. Del Val, M., Schlicht, H. J., Ruppert, T., Reddehase, M. J., and Koszinowski, U. H., Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein, Cell, 66, 1145-1153, 1991.
14. Spies, T. and DeMars, R., Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter see comments, Nature, 351, 323-324, 1991.
15. Kelly, A., Powis, S. H., Kerr, L. A., Mockridge, I., Elliott, T., Bastin, J., Uchanska-Ziegler, B., Ziegler, A., Trowsdale, J., and Townsend, A., Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex, Nature, 355, 641-644, 1992.
16. Neisig, A., Roelse, J., Sijts, A. J. Ossendorp, F., Feltkamp, M. C., Kast, W. M., Melief, C. J., and Neefjes, J. J., Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences, J. Immunol., 154, 1273-1279, 1995.
17. van Endert, P. M., Riganelli, D., Greco, G., Fleischhauer, K., Sidney, J., Sette, A., and Bach, J. F., The peptide-binding motif for the human transporter associated with antigen processing, J. Exp. Med., 182, 1883-1895, 1995.
18. Neefies, J., Gottfried, E., Roelse, J., Gromme, M., Obst, R., Hammerling, G. J., and Momburg, F., Analysis of the fine specificity of rat, mouse and human TAP peptide transporters, Eur. J. Immunol., 25, 1133-1136, 1995.
19. Marusina, K., Reid, G., Gabathuler, R., Jefferies, W., and Monaco, J. J., Novel pepti de-bin ding proteins and peptide transport in normal and TAP-deficient microsomes, Biochemistry, 36, 856-863, 1997.
20. Udono, H., Levey, D. L., and Srivastava, P. K., Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo, Proc. Natl. Acad. Sci. U.S.A., 91, 3077-3081, 1994.
21. Suto, R. and Srivastava, P. K., A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides, Science, 269, 1585-1588, 1995.
22. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G., Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules, Nature, 351, 290-296, 1991.
23. Matsumura, M., Fremont, D. H., Peterson, P. A., and Wilson, I. A., Emerging principles for the recognition of peptide antigens by MHC class I molecules, Science, 257, 927-934, 1992.
24. Morrison, J., Elvin, J., Latron, F., Gotch, F., Moots, R., Strominger, J. L., and McMichael, A., Identification of the nonarner peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes, Eur. J. Immunol., 22, 903-907, 1992.
25. Fremont, D. H., Matsumura, M., Stura, E. A., Peterson, P. A., and Wilson, I. A., Crystal structures of two viral peptides in complex with murine MHC class I H-2Kb, Science, 257, 919-927, 1992.
26. Rotzschke, O., Falk, K., Stevanovic, S., Jung, G., Walden, P., and Rammensee, H. G., Exact prediction of a natural T cell epitope, Eur. J. Immunol., 21; 2891-2894, 1991.
27. Hunt, D. F., Henderson, R. A., Shabanowitz, J., Sakaguchi, K., Michel, H., Sevilir, N., Cox, A. L., Appella, E., and Engelhard, V. H., Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry, Science, 255, 1261-1263, 1992.
28. Hunt, D. F., Michel, H., Dickinson, T. A., Shabanowitz, J., Cox, A. L., Sakaguchi, K., Appella, E., Grey, H. M., and Sette, A., Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad, Science, 256, 1817-1820, 1992.
29. Huang, A. Y. C., Gulden, P. H., Woods, A. S., Thomas, M. C., Tong, C. D., Wang, W., Engelhard, V. H., Pasternack, G., Cotter, R., Hunt, D., Pardoll, D. M., and Jaffee, E. M., The immunodominant major histocompatibility complex class 1-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product, Proc. Natl. Acad. Sci. U.S.A., 93, 9730-9735, 1996.
30. Parker, K. C., Bednarek, M. A., and Coligan, J. E., Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains, J. Immunol., 152, 163-175, 1994.
31. D'Amaro, J., Houbiers, J. G., Drijfhout, J. W., Brandt, R. M., Schipper, R., Bavinck, J. N., Melief, C. J., and Kast, W. M., A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs, Hum. Immunol., 43, 13-18, 1995.
32. Nijman, H. W., Houbiers, J. G., Vierboom, M. P., van der Burg, S. H., Drijfhout, J. W., D'Amaro, J., Kenemans, P., Melief, C. J., and Kast, W. M., Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes, Eur. J. Immunol., 23, 1215-1219, 1993.
33. Geysen, H. M., Meloen, R. H., and Barteling, S. J., Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid, Proc. Natl Acad, Sci. U.S.A., 81, 3998-4002, 1984.
34. Geysen, H. M., Barteling, S. J., and Meloen, R. H., Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein, Proc. Natl. Acad. Sci. U.S.A., 82, 178-182, 1985.
35. Maeji, N. J., Bray, A. M., and Geysen, H. M., Multipin peptide synthesis strategy for T cell determinant analysis, J. Immunol., Methods, 134, 23-33, 1990.
36. Kast, W. M., Offringa, R., Peters, P. J., Voordouw, A. C., Meloen, R. H., van der Eb, A. J., and Melief, C. J., Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes, Cell, 59, 603-614, 1989.
37. van der Zee, R., Van Eden, W., Meloen, R. H., Noordzij, A., and Van Embden, J. D., Efficient mapping and characterization T cell epitope by the simultaneous synthesis of multiple peptides, Eur. J. Immunol., 19, 43-47, 1989.
38. Salter, R. D. and Cresswell, P., Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid, EMBO J., 5, 943-949, 1986.
39. Ljunggren, H. G. Stam, N. J., Ohlen, C., Neefjes, J. J., Hoglund, P., Heemels, M. T., Bastin, J., Schumacher, T. N., Townsend, A., Karre, K., et al., Empty MHC class I molecules come out in the cold, Nature, 346, 476-480, 1990.
40. De Bruijn, M. L., Schumacher, T. N., Nieland, J. D., Ploegh, H. L., Kast, W. M., Melief, C. J. M., and Melief, C. J., Peptide loading of empty major histocompatibility complex molecules on RMA-S cells allows the induction of primary cytotoxic T lymphocyte responses, Eur. J. Immunol., 21, 2963-2970, 1991.
41. Stauss, H. J., Davies, H., Sadovnikova, E., Chain, B., Horowitz, N., and Sinclair, C., Induction of cytotoxic T lymphocytes with peptides in vitro: identification of candidate T-cell epitopes in human papilloma virus, Proc. Natl. Acad. Sci. U.S.A., 89, 7871-7875, 1992.
42. Mandelboim, O., Berke, G., Fridkin, M., Feldman, M., Eisenstein, M., and Eisenbach, L., CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma, Nature, 369, 67-71, 1994.
43. Townsend, A., Elliott, T., Cerundolo, V., Foster, L., Barber, B., and Tse, A., Assembly of MHC class I molecules analyzed in vitro, Cell, 62, 285-295, 1990.
44. Elvin, J., Potter, C., Elliott, T., Cerundolo, V., and Townsend, A., A method to quantify binding of unlabeled peptides to class I MHC molecules and detect their allele specificity, J. Immunol. Methods, 158, 161-171, 1993.
45. Elvin, J., Cerundolo, V., Elliott, T., and Townsend, A., A quantitative assay of peptide-dependent class I assembly, Eur. J. Immunol., 21, 2025-2031, 1991.
46. Ruppert, J., Sidney, J., Celis, E., Kubo, R. T., Grey, H. M., and Sette, A., Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules, Cell, 74, 929-937, 1993.
47. Sette, A., Sidney, J., Del Guercio, M. F., Southwood, S., Ruppert, J., Dahlberg, C., Grey, H. M., and Kubo, R. T., Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays, Mol. Immunol., 31, 813-822, 1994.
48. Blake, J., Johnston, J. V., Hellstrom, K. E., Marquardt, H., and Chen, L., Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes, J. Exp. Med., 184, 121-130, 1996.
49. Gavin, M. A., Dere, B., Grandea, A. G., 3rd, Hogquist, K. A., and Bevan, M. J., Major histocompatibility complex class I allele-specific peptide libraries: identification of peptides that mimic an H-Y T cell epitope, Eur. J. Immunol., 24, 2124-2133, 1994.
50. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J., Oseroff, C., Yuan, L., Ruppert, J., et al., The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes, J. Immunol., 153, 5586-5592, 1994.
51. van der Burg, S. H., Visseren, M. J., Brandt, R. M., Kast, W. M., and Melief, C. J., Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability, J. Immunol., 156, 3308-3314, 1996.
52. Celis, E., Tsai, V., Crimi, C., DeMars, R., Wentworth, P. A., Chesnut, R. W., Grey, H. M., Sette, A., and Serra, H. M., Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes, Proc. Natl. Acad. Sci. U.S.A., 91, 2105-2109, 1994.
53. Bakker, A. B., Marland, G., deBoer, A. J., Huijbens, R. J., Danen, E. H., Adema, G. J., and Figdor, C. G., Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro, Cancer Res., 55, 5330-5334, 1995.
54. Plebanski, M., Allsopp, C. E., Aidoo, M., Reyburn, H., and Hill, A. V., Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood, Eur. J. Immunol., 25, 1783-1787, 1995.
55. Ressing, M. E., Sette, A., Brandt, R. M., Ruppert, J., Wentworth, P. A., Hartman, M., Oseroff, C., Grey, H. M., Melief, C. J., and Kast, W. M., Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides, J Immunol., 154, 5934-5943, 1995.
56. van der Burg, S. H., Klein, M. R., van de Velde, C. J., Kast, W. M., Miedema, F., and Melief, C. J., Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase, AIDS, 9, 121-127, 1995.
57. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M., and Melief, C. J., In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53, Eur. J. Immunol, 23, 2072-2077, 1993.
58. Gagliardi, M. C., De Petrillo, G., Salemi, S., Boffa, L., Longobardi, M. G., Dellabona, P., Casorati, G., Tanigaki, N., Harris, R., Lanzavecchia, A., et al., Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro, Int. Immunol., 7, 1741-1752, 1995.
59. Tsai, V., Southwood, S., Sidney, J., Sakaguchi, K., Kawakami, Y., Appella, E., Sette, A., and Celis, E., Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells, J. Immunol., 158, 1796-1802, 1997.
60. Alijagic, S., Moller, P., Artuc, M., Jurgovsky, K., Czarnetzki, B. M., and Schadendorf, D., Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation, Eur. J. Immunol., 25, 3100-3107, 1995.
61. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W., Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex J. Exp. Med., 173, 1007-1015, 1991.
62. Ressing, M. E., van Driel, W. J., Celis, E., Sette, A., Brandt, R. M. P., Hartman, M., Anholts, J. D. H., Schreuder, G. M. T., Bram ter Harmsel, W., Fleuren, G. J., Trimbios, B. J., Kast, W. M., and Melief, C. J. M., Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope, Cancer Res., 56, 582-588, 1996.
63. Schonbach, C., Nokihara, K., Bangham, C. R., Kariyone, A., Karaki, S., Shida, H., Takatsu, K., Egawa, K., Wiesmuller, K. H., and Takiguchi, M., Identification of HTLV-1-specific CTL directed against synthetic and naturally processed peptides in HLA-B*3501 transgenic mice, Virology, 226, 102-112, 1996.
64. Lustgarten, J., Theobald, M., Labadie, C., Laface, D., Peterson, P., Disis, M. L., Cheever, M. A., and Sherman, L. A., Identification of Her-2/neu CTL epitopes using bouble transgenic mice expressing HLA-A2.1 and human CD.8, Hum. Immunol., 52, 109-118, 1997.
65. Greenberg, P. D., Klarnet, J. P., Kern, D. E., and Cheever, M. A., Therapy of disseminated tumors by adoptive transfer of specifically immune T cells, Progr. Exp. Tumor Res., 32, 104-127, 1988.
66. Klarnet, J. P., Kern, D. E., Okuno, K., Holt, C., Lilly, F., and Greenberg, P. D., FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens, J. Exp. Med., 169, 457-467, 1989.
67. Toes, R. E., Offringa, R., Blom, R. J., Brandt, R. M., van der Eb, A. J., Melief, C. J., and Kast, W. M., An adenovirus type 5 early region IB-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene, J. Immunol., 154, 3396-3405, 1995.
68. Feltkamp, M. C., Vreugdenhil, G. R., Vierboom, M. P., Ras, E., van der Burg, S. H., ter Schegget, J., Melief, C. J., and Kast, W. M., Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors, Eur. J. Immunol., 25, 26382642, 1995.
69. Riddell, S. R., Watanabe, K. S., Goodrich, J. M., Li, C. R., Agha, M. E., and Greenberg, P. D., Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones, Science, 257, 238-241, 1992.
70. Schulz, M., Zinkernagel, R. M., and Hengartner, H., Peptide-induced antiviral protection by cytotoxic T cells, Proc. Natl. Acad. Sci. U.S.A., 88, 991-993, 1991.
71. Kast, W. M., Roux, L., Curren, J., Blom, H. J., Voordouw, A. C., Meloen, R. H., Kolakofsky, D., and Melief, C. J., Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide, Proc. Natl. Acad. Sci. U.S.A., 88, 2283-2287, 1991.
72. Melief, C. J. and Kast, W. M., T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes, Immunol. Rev., 145, 167-177, 1995.
73. Cannistra, S. A. and Niloff, J. M., Cancer of the uterine cervix, N. Engl. J. Med., 334, 1030-1038, 1996.
74. Feltkamp, M. C., Smits, H. L., Vierboom, M. P., Minnaar, R. P., de Jongh, B. M., Drijfhout, J. W., ter Schegget, J., Melief, C. J., and Kast, W. M., Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells, Eur. J. Immunol., 23, 2242-2249, 1993.
75. Mayordomo, J. I., Zorina, T., Storkus, W. J., Zitvogel, L., Celluzzi, C., Falo, L. D., Melief, C. J., Ildstad, S. T., Kast, W. M., Deleo, A. B., et al., Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity, Nature Med., 1, 1297-1302, 1995.
76. Cullis, J. O., Barrett, A. J., Goldman, J. M., and Lechler, R. I., Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen-processing defective cell lines, Leukemia, 8, 165-170, 1994.
77. Mcintyre, C. A., Rees, R. C., Platts, K. E., Cooke, C. J., Smith, M. O., Mulcahy, K. A., and Murray, A. K., Identification of peptide epitopes of Mage-1, -2, -3 that demonstrate HLA-A3-specific binding, Cancer Immunol. Immunother., 42, 246-250, 1996.
78. Visseren, M. J. W., van der Burg, S. H., van der Voort, E. I. H., Brandt, R. M. P., Schrier, P. I., Van der Bruggen, P., Boon, T., Melief, C. J. M., and Kast, W. M., Identification of HLA-A*0201 -restricted CTL epitopes encoded by the tumor-specific MAGE-2 gene product, Int. J. Cancer, in press, 1997.
79. Domenech, N., Henderson, R. A., and Finn, O. J., Identification of an HLA-A11 -restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin, J. Immunol., 155, 4766-4774, 1995.
80. Gnjatic, S., Bressac-de Paillerets, B., Guillet, J. G., and Choppin, J., Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules, Eur. J. Immunol., 25, 1638-1642, 1995.
81. Ropke, Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., Vanderburg, S., Nijman, H. W., Melief, C. J. M., and Claesson, M. H., Tumor immunology, tumor antigens, T cell, cytotoxicity, Hla, and restriction. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide, Proc.-Natl. Acad. Sci. U.S.A., 93, 14704-14707, 1996.
82. Brichard, V. G., Herman, J., VanPel, A., Wildmann, C., Gaugler, B., Wolfel, T., Boon, T., and Lethe, B., A tyrosinase nonapeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes, Eur. J. Immunol., 26, 224-230, 1996.
83. Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor, C. G., Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes, J. Exp. Med., 179, 1005-1009, 1994.
84. Visseren, M. J., Van Elsas, A., van der Voort, E. I., Ressing, M. E., Kast W. M., Schrier, P. I., and Melief, C. J., CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells, J. Immunol., 154, 3991-3998, 1995.
85. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr., Identification of a peptide recognized by five melanomaspecific human cytotoxic T cell lines, Science, 264, 716-719, 1994.
86. Disis, M. L., Gralow, J. R., Bernhard, H., Hand, S. L., Rubin, W. D., and Cheever, M. A., Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein, J. Immunol., 156, 3151-3158, 1996.
87. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., Decesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E., Deleo, A. B., and De Cesare, C. M., Therapy of murine tumors with P53 wild-type and mutant sequence peptide-based vaccines, J. Exp. Med., 183, 1357-1365, 1996.
88. Vandenbark, A. A., Chou, Y. K., Whitham, R., Mass, M., Buenafe, A., Liefeld, D., Kavanagh, D., Cooper, S., Hashim, G. A., Offner, H., and Bourdette, D. N., Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial, Nature Med., 2, 1109-1115, 1996.
89. Gorse, G. J., Reefer, M. C., Belshe, R. B., Matthews, T. J., Forrest, B. D., Hsieh, R. H., Koff, W. C., Hanson, C. V., Dolin, R., Weinhold, K. J., Frey, S. E., Ketter, N., and Fast, P. E., A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group, J. Infect. Dis., 173, 330-339, 1996.
90. Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., La Fond, R., Yuan, L., Chisari, F. V., Furze, J., Bartholomeuz, R., et al., Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans, J. Clin. Invest., 95, 341-349, 1995.
91. Penna, A., Chisari, F. V., Bertoletti, A., Missale, G., Fowler, P., Giuberti, T., Fiaccadori, F., and Ferrari, C., Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen, J. Exp. Med., 174, 1565-1570, 1991.
92. Kumar, A., Arora, R., Kaur, P., Chauhan, V. S., and Sharma, P., "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide, J. Immunol., 148, 1499-1505, 1992.
93. Schild, H., Norda, M., Deres, K., Falk, K., Rotzschke, O., Wiesmullef, K. H., Jung, G., and Rammensee, H. G., Fine specificity of cytotoxic T lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide, J. Exp. Med., 174, 1665-1668, 1991.
94. Jaeger, E., Bernhard, H., Romero, P., Ringhoffer, M., Arand, M., Karbach, J., Ilsemann, C., Hagedorn, M., and Knuth, A., Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens, Int. J. Cancer, 66, 162-169, 1996.
95. Salgaller, M. L., Marincola, F. M., Cormier, J. N., and Rosenberg, S. A., Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides, Cancer Res., 56, 4749-4757, 1996.
96. Cormier, J. N., Salgaller, M. L., Prevette, T., Barracchini, K. C., Rivoltini, L., Restifo, N. P., Rosenberg, S. A., and Marincola, F. M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A, Cancer J. Sci. Am., 3, 37-44, 1997.
97. Goydos, J. S., Elder, E., Whiteside, T. L., Finn, O. J., and Lotze, M. T., A phase 1 trial of a synthetic mucin peptide vaccine induction of specific immune reactivity in patients with adenocarcinoma, J. Surg. Res., 63, 298-304, 1996.
98. Kast, W. M., Ressing, M. E., Brandt, R. M. P., Trimbos, B. J., Fleuren, G. J., ter Schegget, J., and Melief, C. J. M., The HPV16 E7 peptide-based vaccine trial in end stage cervical carcinoma. An interim report, 15th Int. Papillomavirus Workshop, Queensland, Australia, Dec. 1-9, 1996.
99. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R., Kurtzman, S. K., Ergin, M. T., Ozols, J., Meehan, J., et al., Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells, Proc. Natl. Acad. Sci. U.S.A., 92, 8078-8082, 1995.
100. Hu, X., Chakraborty, N. G., Sporn, J. R., Kurtzman, S. H., Ergin, M. T., and Mukherji, B., Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen-presenting cell-based vaccine, Cancer Res., 56, 2479-2483, 1996.
101. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Solheim, B. G., Soreide, O., Thorsby, E., and Gaudernack, G., Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation, Lancet, 346, 1399-1400, 1995.
102. Gjertsen, M. K., Bakka, A., Breivik, J., Saeterdal, I., Gedde-Dahl, Stokke, K. T., Solheim, B. G., Egge, T. S., Soreide, O., Thorsby, E., and Gaudernack, G., Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study, Int. J. Cancer, 65, 450-453, 1996.
103. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A., Phase I clinical trial: T-Cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen, Prostate, 29, 371-380, 1996.
104. Tjoa, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L., and Murphy, G., Dendritic cell, T-cell response, and prostate-specific membrane antigen. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity, Prostate, 28, 65-69, 1996.
105. Toes, R. E., Blom, R. J., Offringa, R., Kast, W. M., and Melief, C. J., Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors, J. Immunol., 156, 3911-3918, 1996.
106. Toes, R.E.M., Offringa, R., Blom, R.J.J., Melief, C. J. M., and Kast, W. M., Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction, Proc. Natl. Acad. Sci. U.S.A., 93, 7855-7860, 1996.
107. Aichele, P., Kyburz, D., Ohashi, P. S., Odermatt, B., Zinkernagel, R. M., Hengartner, H., and Pircher, H., Peptide-induced T-cell tolerance to prevent autoimmune diabetes in a transgenic mouse model, Proc. Natl Acad. Sci. U.S.A., 91, 444-448, 1994.
108. Aichele, P., Brduscha-Riem, K., Zinkernagel, R. M., Hengartner, H., and Pircher, H., T cell priming versus T cell tolerance induced by synthetic peptides, J. Exp. Med., 182, 261-266, 1995.
109. Grohmann, U., Bianchi, R., Fioretti, M. C., Fallarino, F., Binaglia, L., Uyttenhove, C., Van Pel, A., Boon, T., and Puccetti, P., CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum-or helper peptides in priming for skin test reactivity to a P815AB-related peptide, Eur. J. Immunol., 25, 2797-2802, 1995.
110. Grohmann, U., Bianchi, R., Ayroldi, E., Belladonna, M. L., Surace, D., Fioretti, M. C., and Puccetti, P., A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state, J. Immunol., 158, 3593-3602, 1997.
111. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., and Schiller, J. T., Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic, Proc. Natl. Acad. Sci. U.S.A., 89, 12180-12184, 1992.
112. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R., and Schiller, J. T., Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles, J. Virol., 67, 6929-6936, 1993.
113. Roden, R. B., Kirnbauer, R., Jenson, A. B., Lowy, D. R., and Schiller, J. T., Interaction of papillo-maviruses with the cell surface, J. Virol., 68, 7260-7266, 1994.
114. Muller, M., Gissmann, L., Cristiano, R. J., Sun, X. Y., Frazer, I. H., Jenson, A. B., Alonso, A., Zentgraf, H., and Zhou, J., Papillomavirus capsid binding and uptake by cells from different tissues and species, J. Virol., 69, 948-954, 1995.
115. Evander, M., Frazer, I. H., Payne, E., Qi, Y. M., Hengst, K., and McMillan, N. A., Identification of the alpha6 integrin as a candidate receptor for papillomaviruses, J. Virol., 71, 2449-2456, 1997.
116. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T., and Falo, L. D., Jr., Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity, J. Exp. Med., 183, 283-287, 1996.
117. Barrios, C., Lussow, A. R., Van Embden, J., van der Zee, R., Rappuoli, R., Costantino, P., Louis, J. A., Lambert, P. H., and Del Giudice, G., Mycobacterial heat-shock proteins as carrier molecules. II. The use of the 70-kDa mycobacterial heat-shock protein as carrier for conjugated vaccines can circumvent the need for adjuvants and Bacillus Calmette Guerin priming, Eur. J. Immunol., 22, 1365-1372, 1992.
118. Heike, M., Noll, B., and Meyer zum Buschenfelde, K. H., Heat shock protein-peptide complexes for use in vaccines, J. Leuk. Biol., 60, 153-158, 1996.
119. Roman, E. and Moreno, C., Synthetic peptides non-covalently bound to bacterial hsp 70 elicit peptide-specific T-cell responses in vivo, Immunology, 88, 487-492, 1996.
120. Spooner, R. A., Deonarain, M. P., and Epenetos, A. A., DNA vaccination for cancer treatment, Gene Therapy, 2, 173-180, 1995.
121. Ulmer, J. B., Donnelly, J. J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V. J., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., Hawe, L. A., Leander, K. R., Martinez, D., Perry, H. C., Shiver, J. W., Montgomery, D. L., and Liu, M. A., Heterologous protection against influenza by injection of DNA encoding a viral protein, Science, 259, 1745-1749, 1993.
122. Conry, R. M., LoBuglio, A. F., Kantor, J., Schlom, J., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Abrams, S., and Curiel, D. T., Immune response to a carcinoembryonic antigen polynucleotide vaccine, Cancer Res., 54, 1164-1168, 1994.
123. Conry, R. M., LoBuglio, A. F., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., Pike, J., and Curiel, D. T., A carcinpembryonic antigen polynucleotide vaccine for human clinical use, Cancer Gene Therapy, 2, 33-38, 1995.
124. Acres, R. B., Hareuveni, M., Balloul, J.-M., and Kieny, M.-P., Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen, J. Immunother., 14, 136-143, 1993.
125. Oldstone, M. B., Tishon, A., Eddleston, M., de la Torre, J. C., McKee, T., and Whitton, J. L., Vaccination to prevent persistent viral infection, J. Virol., 61, 4372-4378, 1993.
126. Whitton, J. L., Sheng, N., Oldstone, M. B., and McKee, T. A., A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge, J. Virol 67, 348-352, 1993.
127. Thomson, S. A., Khanna, R., Gardner, J., Burrows, S. R., Coupar, B., Moss, D. J., and Suhrbier, A., Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design, Proc. Natl. Acad. Sci. U.S.A., 92, 5845-5849, 1995.
128. Thomson, S. A., Elliott, S. L., Sherritt, M. A., Sproat, K. W., Coupar, B. E., Scalzo, A. A., Forbes, C. A., Ladhams, A. M., Mo, X. Y., Tripp, R. A., Doherty, P. C., Moss, D. J., and Suhrbier, A., Recombinant polyepitope vaccines for the delivery of multiple CDS cytotoxic T cell epitopes, J. Immunol., 157, 822-826, 1996.
129. Boczkowski, D., Nair, S. K., Snyder, D., and Gilboa, E., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo, J. Exp. Med., 184, 465-472, 1996.
130. Traversari, C., Van der Bruggen, P., Luescher, I. F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A., and Boon, T., A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E, J. Exp. Med., 176, 1453-1457, 1992.
131. Van der Bruggen, P., Szikora, J. P., Boel, P., Wildmann, C., Somville, M., Sensi, M., and Boon, T., Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing HLA Cw*1601, Eur. J. Immunol, 24, 2134-2140, 1994.
132. Van der Bruggen, P., Bastin, J., Gajewski, T., Coulie, P. G., Boel, P., De Sme, C., Traversari, C., Townsend, A., and Boon, T., A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3, Eur. J. Immunol., 24, 3038-3043, 1994.
133. Herman, J., Van der Bruggen, P., Luescher, I. F., Mandruzzato, S., Romero, P., Thonnard, J., Fleischhauer, K., Boon, T., and Coulie, P. G., A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3, Immunogenetics, 43, 377-383, 1996.
134. Boel, P., Wildmann, C., Sensi, M. L., Brasseur, R., Renauld, J. C., Coulie, P., Boon, T., and Van der Bruggen, P., BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes, Immunity, 2, 167-175, 1995.
135. Van den Eynde, B., Peeters, O., De Backer, O., Gaugler, B., Lucas, S., and Boon, T., A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma, J. Exp. Med., 182, 689-698, 1995.
136. Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De
137. Gaugler, B., Brouwenstijn, N., Vantomme, V., Szikora, J. P., Van der Spek, C. W., Patard, J. J., Boon, T., Schrier, P., and Van den Eynde, B. J., A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma, Immunogenetics, 44, 323-330, 1996.
138. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P. F., Rivoltini, L., Yannelli, J. R., Appella, E., and Rosenberg, S. A., Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes, J. Exp. Med., 180, 347-352, 1994.
139. Castelli, C., Storkus, W. J., Maeurer, M. J., Martin, D. M., Huang, E. C., Pramanik, B. N., Nagabhushan, T. L., Parmiani, G., and Lotze, M. T., Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes, J. Exp. Med., 181, 363-368, 1995.
140. Kawakami, Y., Eliyahu, S., Jennings, C., Sakaguchi, K., Kang, X., Southwood, S., Robbins, P. F., Sette, A., Appella, E., and Rosenberg, S. A., Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression, J. Immunol., 154, 3961-3968, 1995.
141. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A., Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection, Proc. Natl Acad. Sci. U.S.A., 91, 6458-6462, 1994.
142. Bakker, A. B., Schreurs, M. W., Tafazzul, G., de Boer, A. J., Kawakami, Y., Adema, G. J., and Figdor, C. G., Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted anti-melanoma CTL line, Int. J. Cancer, 62, 97-102, 1995.
143. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H., and Boon, T., Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes, Eur. J. Immunol., 24, 759-764, 1994.
144. Kang, X., Kawakami, Y., El-Gamil, M., Wang, R., Sakaguchi, K., Yannelli, J. R., Appella, E., Rosenberg, S. A., and Robbins, P. F., Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes, J. Immunol., 155, 1343-1348, 1995.
145. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J., Generation of human cytotoxic T cells specific for human carcino-embryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, J. Natl. Cancer Inst., 87, 982-990, 1995.
146. Robbins, P. F., El-Gamil, M., Kawakami, Y., and Rosenberg, S. A., Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy, Cancer Res., 54, 3124-3126, 1994.
147. Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., and Rosenberg, S. A., A mutated beta-catenin gene encodes a melanomaspecific antigen recognized by tumor infiltrating lymphocytes, J. Exp. Med., 183, 1185-1192, 1996.
148. Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T., A mutated intron sequence code for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma, Proc. Natl. Acad. Sci. U.S.A., 92, 7976-7980, 1995.
149. Xue, B. H., Zhang, Y., Sosman, J. A., and Peace, D. J., Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen, Prostate, 30, 73-78, 1997.
150. Correale, P., Walmsley, K., Nieroda, C., Zaremba, S., Zhu, M., Schlom, J., and Tsang, K. Y., In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from pro state-specific antigen, J. Natl. Cancer Inst., 89, 293-300, 1997.
151. Nijman, H. W., van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, W. M., and Melief, C. J., A potential target for tumor-directed T cells, p53, Immunol. Lett., 40, 171-178, 1994.
152. Van Elsas, A., Nijman, H. W., Van der Minne, C. E., Mourer, J. S., Kast, W. M., Melief, C. J., and Schrier, P. I., Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201, Int. J. Cancer, 61, 389-396, 1995.
153. Fisk, B., Blevins, T. L., Wharton, J. T., and Ioannides, C. G., Identification of an immuno-dominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, J. Exp. Med., 181, 2109-2117, 1995.
154. Peoples, G. E., Goedegebuure, P. S., Smith, R., Linehan, D. C., Yoshino, I., and Eberlein, T. J., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide, Proc. Natl. Acad. Sci. U.S.A., 92, 432-436, 1995.
155. Yoshino, I., Peoples, G. E., Goedegebuure, P. S., Maziarz, R., and Eberlein, T. J., Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer, J. Immunol., 152, 2393-2400, 1994.
156. Greco, G., Fruci, D., Accapezzato, D., Barnaba, V., Nisini, R., Alimena, G., Montefusco, E., Vigneti, E., Butler, R., Tanigaki, N., and Tosi, R., Two bcr-abl junction peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes, Leukemia, 10, 693-699, 1996.
157. Bertoletti, A., Costanzo, A., Chisari, F. V., Levrero, M., Artini, M., Sette, A., Penna, A., Giuberti, T., Fiaccadori, F., and Ferrari, C., Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope, J. Exp. Med., 180, 933-943, 1994.
158. Tsai, S. L., Chen, M. H., Yeh, C. T., Chu, C. M., Lin, A. N., Chiou, F. H., Chang, T. H., and Liaw, Y. F., Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes, J. Clin. Invest., 97, 577-584, 1996.
159. Lee, S. P., Thomas, W. A., Murray, R. J., Khanim, F., Kaur, S., Young, L. S., Rowe, M., Kurilla, M., and Rickinson, A. B., HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2, J. Virol., 67, 7428-7435, 1993.
160. Hill, A. B., Lee, S. P., Haurum, J. S., Murray, N., Yao, Q. Y., Rowe, M., Signoret, N., Rickinson, A. B., and McMichael, A. J., Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised, J. Exp. Med., 181, 2221-2228, 1995.
161. Zhang, Q. J., Gavioli, R., Klein, G., and Masucci, M. G., An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins, Proc. Natl. Acad. Sci. U.S.A., 90, 2217-2221, 1993.
162. Koenig, S., Woods, R. M., Brewah, Y. A., Newell, A. J., Jones, G. M., Boone, E., Adelsberger, J. W., Baseler, M. W., Robinson, S. M., and Jacobson, S., Characterization of MHC class I-restricted cytotoxic T cell responses to tax in HTLV-1-infected patients with neurologic disease, J. Immunol., 151, 3874-3883, 1993.